AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19015204
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ointment 0.03% applied once daily, 3 times per week
Trial: 19015204
Drug: Vehicle applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle applied once daily, 3 times per week
Trial: 12647487
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (HRT)
Trial: 9782217
Drug: Dey combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dey combination solution (albuterol-ipratropium)
Trial: 8145958
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg once daily for 4 weeks
Trial: 8145958
Drug: Griseofulvin 500
RxNorm normalized name: griseofulvin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 500 mg once daily for 4 weeks
Trial: 3139877
Drug: Methotrexate 10
RxNorm normalized name: methotrexate 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 10 mg IM weekly
Trial: 3139877
Drug: Sodium aurothiomalate
RxNorm normalized name: Sodium aurothiomalate
DrugBank: Sodium aurothiomalate (DB09276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium aurothiomalate (GSTM) 50 mg IM weekly
Trial: 31532277
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (CT) involving intramuscular testosterone injection and testosterone ointment application
Trial: 31532277
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection monotherapy (IMIM)
Trial: 30529119
Drug: Topical heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical heparin treatment
Trial: 26091244
Drug: aTIV after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aTIV after control vaccine
Trial: 24334642
Drug: Verbal assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal assessments administered in-person
Trial: 19294693
Drug: Atorvastatin (ATV)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (ATV) 80 mg/dL for two months (n = 14)
Trial: 19294693
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (CT) for two months (n = 11)
Trial: 15470336
Drug: 750 mL
RxNorm normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mL red wine (13.5% by volume)
Trial: 15470336
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sildenafil and red wine
Trial: 30905430
Drug: Behavioral weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral weight loss intervention with weekly self-monitoring, tailored feedback on diet and exercise goals, and dietitian and provider counseling.
Trial: 25784358
Drug: Ranibizumab monotherapy
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab monotherapy (RM)
Trial: 25784358
Drug: Ranibizumab plus
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab plus verteporfin photodynamic therapy (RV)
Trial: 24026876
Drug: Cisplatin/pirarubicin (CITA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/pirarubicin (CITA) chemotherapy
Trial: 24026876
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) with stem cell transplantation (SCT)
Trial: 19154270
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg orally for 3 days before orthodontic activation
Trial: 19154270
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg orally for 3 days after orthodontic activation
Trial: 17410029
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (G) 1250 mg/m, given on days 1 and 14, repeated every 28 days for up to four cycles.
Trial: 17410029
Drug: Gemcitabine-carboplatin (GCb)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine-carboplatin (GCb) 1250 mg/m of G plus carboplatin area under the curve of 3, given on days 1 and 14, repeated every 28 days for up to four cycles.
Trial: 11479880
Drug: sICAM‐1 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sICAM‐1 levels in group III (1760.0 ± 717.5 ng/mL)
Trial: 11479880
Drug: sVCAM‐1 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sVCAM‐1 levels in group III (1932.9 ± 282.6 ng/mL)
Trial: 11479880
Drug: sVCAM‐1 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sVCAM‐1 levels in group II with portal hypertension (PH) (1253.0 ± 245.1 ng/mL)
Trial: 9510981
Drug: Dolasetron mesylate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron mesylate, 200 mg after a high-fat breakfast
Trial: 9510981
Drug: Dolasetron mesylate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron mesylate, 200 mg after an overnight fast
Trial: 9063763
Drug: 1 g.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g. day-1 of allithiamine for 5 days
Trial: 1946576
Drug: Theophylline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (100 mg/kg/day)
Trial: 1946576
Drug: Propranolol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (25 mg/kg/day)
Trial: 1946576
Drug: Propranolol (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (higher dose)
Trial: 7053279
Drug: Verapamil (240,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240, 360, and 480 mg/day)
Trial: 24245960
Drug: Standard-dose prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose prasugrel
Trial: 24245960
Drug: Double maintenance-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double maintenance-dose clopidogrel
Trial: 22586253
Drug: Arterolane maleate
RxNorm normalized name: maleate
DrugBank: Arterolane (DB19027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arterolane maleate plus piperaquine phosphate (AM-PQP) 150 mg and 750 mg respectively
Trial: 18341677
Drug: Tolevamer potassium
RxNorm normalized name: Potassium
DrugBank: Tolevamer (DB01344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolevamer potassium sodium 15 g day(-1) for 9 days
Trial: 18341677
Drug: Tolevamer potassium
RxNorm normalized name: Potassium
DrugBank: Tolevamer (DB01344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolevamer potassium sodium 6 g day(-1) for 9 days
Trial: 15715683
Drug: Dual ETA/ETB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual ETA/ETB receptor antagonism with BQ123 and BQ788 (10 nmol min(‐1)) during ramipril treatment
Trial: 15715683
Drug: Ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 10 mg o.d. for 3 months
Trial: 9371403
Drug: BEP (bleomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEP (bleomycin, etoposide, and cisplatin) chemotherapy
Trial: 4019953
Drug: 6‐methyl‐prednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐methyl‐prednisolone (1 mg/kg) intravenous bolus
Trial: 4019953
Drug: 6‐methyl‐prednisolone (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐methyl‐prednisolone (32 mg once a day, orally) for 8 days
Trial: 29522226
Drug: Nepafenac 0.3%
RxNorm normalized name: NEPAFENAC 0.3% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac 0.3% ophthalmic suspension once daily
Trial: 29522226
Drug: Nepafenac 0.1%
RxNorm normalized name: NEPAFENAC 0.1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac 0.1% ophthalmic suspension three times a day
Trial: 26386921
Drug: Bosentan 4
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 4 mg/kg twice-daily (can be down-titrated to 2 mg/kg if not tolerated)
Trial: 26386921
Drug: Bosentan 4
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 4 mg/kg twice-daily
Trial: 22994348
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with house dust mite allergen extracts
Trial: 17321581
Drug: Grass pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass pollen mix (sublingual immunotherapy) for 2 years
Trial: 17321581
Drug: Grass pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass pollen mix (sublingual immunotherapy)
Trial: 26947668
Drug: Watermelon extract
RxNorm normalized name: watermelon extract 50 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon extract (6 g daily for 6 weeks)
Trial: 23430142
Drug: 1% (w/w)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% (w/w) AHYP cream applied twice daily for 4 weeks
Trial: 23430142
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream applied twice daily for 4 weeks
Trial: 21138533
Drug: n‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 PUFA (2 g/day) and antioxidant vitamins C (1 g/day) and E (400 IU/day)
Trial: 12525463
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (600 micro g every 3 h for a maximum of three doses)
Trial: 12525463
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (600 micro g every 3 h for a maximum of three doses)
Trial: 10865219
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (25 mg twice daily) plus calcium (1000 mg/day)
Trial: 10865219
Drug: Intermittent etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent etidronate (400 mg/day for 14 days) followed by calcium (1000 mg/day for 76 days)
Trial: 25617159
Drug: Dexmedetomidine (min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (min 0.2 µg/kg/h‐max 1.0 µg/kg/h)
Trial: 25617159
Drug: Propofol (min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (min 1.0 mg/kg/h‐max 3.0 mg/kg/h)
Trial: 23724525
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate (MPA) for three months
Trial: 23724525
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate (MPA) for six months
Trial: 20816027
Drug: Topiramate (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d)
Trial: 15641760
Drug: Fluoridated milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated milk (5 ppm; total amount 1.25 mg F)
Trial: 11393606
Drug: Multicomponent smoking
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent smoking treatment (MST)
Trial: 11393606
Drug: MST plus
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST plus generalization training of smoking cessation to drug and alcohol cessation (MST+G)
Trial: 11393606
Drug: MST+G
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST+G
Trial: 9252088
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (500 mg/day) plus methotrexate (10 mg/week)
Trial: 3795978
Drug: Yohimbine (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (18 mg yohimbine/day)
Trial: 31694861
Drug: RVT-1502 5
RxNorm normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVT-1502 5 mg
Trial: 31694861
Drug: RVT-1502 10
RxNorm normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVT-1502 10 mg
Trial: 31694861
Drug: RVT-1502 15
RxNorm normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVT-1502 15 mg
Trial: 29394207
Drug: Epidural injections
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injections of local anesthetic with corticosteroid (n = 200)
Trial: 18332704
Drug: Surfactant administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant administration without endotracheal intubation
Trial: 10318654
Drug: Clopidogrel and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel and aspirin (CA group)
Trial: 10318654
Drug: Ticlopidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine and aspirin (TA group)
Trial: 8905888
Drug: Standard chest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chest physical therapy and postural drainage (CPT/PD)
Trial: 28270280
Drug: CTPA on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTPA on high-pitch scanning mode at 70 kV tube voltage with 15 ml contrast medium (Group B)
Trial: 28270280
Drug: CTPA on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTPA on conventional scanning mode (120 kV, 80 ml contrast medium) (Group A)
Trial: 24805262
Drug: DHA (30
RxNorm normalized name: Gesticare DHA (30) Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (30 mg/kg/d)
Trial: 17075807
Drug: Prednisone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (30 mg/day for 2 weeks, 20 mg/day for 1 week, and 10 mg/day for 1 week)
Trial: 7931253
Drug: MDL 72974A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 72974A 1 mg
Trial: 7931253
Drug: MDL 72974A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 72974A 12 mg
Trial: 7931253
Drug: MDL 72974A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 72974A 24 mg
Trial: 18364321
Drug: Taiwanese traditional
RxNorm normalized name: Taiwanese cheesewood whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taiwanese traditional herbal diet (TTHD) consisting of analgesic herbs (paeony root: licorice root=1:1) and Taiwanese tonic vegetable soup (Lilii bulbus, Nelumbo seed, and Jujube fruit)
Trial: 18364321
Drug: Taiwanese tonic
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taiwanese tonic vegetable soup without analgesic herbs (control group)
Trial: 15014006
Drug: Autologous formalin‐fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous formalin‐fixed tumor vaccine (AFTV)
Trial: 12409970
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (75 mg daily) in patients with serum creatinine > 1.3 mg/dl
Trial: 12409970
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (75 mg daily) in subgroups at higher global baseline risk or higher initial blood pressures
Trial: 9613307
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g EMLA (group E)
Trial: 9613307
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml 1% mepivacaine (group M)
Trial: 9613307
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml 0.25% bupivacaine (group B)
Trial: 7584486
Drug: XZ‐CD5 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XZ‐CD5 0.1 mg kg‐1 day‐1 intravenously with high‐dose methyl‐prednisolone for 10, 14 or 17 doses
Trial: 7584486
Drug: XZ‐CD5 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XZ‐CD5 and cyclosporine (CSA) for 17 doses
Trial: 31437302
Drug: DNL104 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNL104 (a centrally penetrant RIPK1 inhibitor)
Trial: 31254640
Drug: Duloxetine 20
RxNorm normalized name: duloxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 20 mg/day titrated to 40 mg/day
Trial: 26576593
Drug: Imatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib plus bevacizumab, 7.5 mg/kg i.v. every 3 weeks
Trial: 26576593
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg (standard) or 800 mg (for patients with exon 9 KIT mutations)
Trial: 23662289
Drug: CR oxycodone/CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR oxycodone/CR naloxone (10 mg/5 mg every 12 h, titrated to 20 mg/10 mg, 30 mg/15 mg, or 40 mg/20 mg)
Trial: 23662289
Drug: CR oxycodone/CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR oxycodone/CR naloxone
Trial: 23356027
Drug: 1 month
RxNorm normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 month of daily rifampin and daily ofloxacin
Trial: 19635893
Drug: 1 year
RxNorm normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 year of WHO MDT plus an initial 1 month of daily rifampin and daily ofloxacin
Trial: 9364542
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m2) as a single agent
Trial: 9364542
Drug: Docetaxel (20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (20% to 21%) after failing cisplatin-based chemotherapy
Trial: 9364542
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) and Cisplatin (75 mg/m2)
Trial: 9364542
Drug: Docetaxel (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (90 mg/m2 without G-CSF support) and Carboplatin
Trial: 9364542
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m2 with G-CSF support) and Carboplatin
Trial: 3629488
Drug: Iron preparations
RxNorm normalized name: IRON PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron preparations combined with vitamins B12 and B6, copper sulfate, and the combination of iron with the vitamin B group and copper sulfate.
Trial: 3629488
Drug: Iron preparations
RxNorm normalized name: IRON PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron preparations administered for injection.
Trial: 3629488
Drug: Subsequent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent therapy after hemoglobin normalization.
Trial: 3629488
Drug: Iron preparations
RxNorm normalized name: IRON PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron preparations combined with other preparations.
Trial: 23844613
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite 200 mcg daily for 6 months
Trial: 20964568
Drug: Topical nitric
RxNorm normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitric oxide 3% plus cryotherapy
Trial: 21186534
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV, 10 mg/d)
Trial: 11982739
Drug: High-dose IFN-alpha
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN-alpha induction therapy (6 MIU daily for 4 weeks and 3 MIU 3/7 days for 22 weeks)
Trial: 11982739
Drug: Conventional IFN-alpha
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional IFN-alpha therapy (3 MIU 3/7 days for 26 weeks)
Trial: 28721881
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy (PORT) at 57.6 Gy or 63 Gy for lower-risk group; 63 Gy or 68.4 Gy for higher-risk group, all at 1.8 Gy per fraction.
Trial: 26297187
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of albumin solution
Trial: 23176678
Drug: Fluoridated milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated milk (5 ppm fluoride, 200 ml daily)
Trial: 23176678
Drug: Non-fluoridated milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fluoridated milk (200 ml daily)
Trial: 15451898
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection of the pylorus (200 units)
Trial: 11165992
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment and prevention options for NSAID-associated ulcers